Literature DB >> 7508319

Comparative effects of neurotensin and neuromedin N on growth of human pancreatic cancer, MIA PaCa-2.

S Sumi1, B M Evers, C M Townsend, K Yoshinaga, T Uchida, M Murakami, K Sato, J Ishizuka, J C Thompson.   

Abstract

Neurotensin (NT), an important regulatory hormone of the gut, stimulates growth of the human pancreatic cancer cell line MIA PaCa-2 in vitro. The purpose of our study was to compare the stimulatory effects of NT and neuromedin N (NMN), a structurally related hexapeptide, on the growth of MIA PaCa-2. In addition, the effects of NT on the growth of MIA PaCa-2 xenografts and normal GI tissues were assessed in athymic nude mice. MIA PaCa-2 cells, plated in serum-free media, were treated with either NT (10(-12)-10(-6) M) or NMN (10(-11)-10(-7) M) and cells were counted. For the in vivo study, MIA PaCa-2 cells were inoculated sc into 30 athymic nude mice and then randomized to two groups to receive either NT (600 micrograms kg-1, sc, tid) or vehicle. At sacrifice (day 35), the xenografted tumours, as well as normal host pancreas, jejunum and ileum were removed, weighed, and assayed for DNA, RNA and protein. Both NT and NMN stimulated the growth of MIA PaCa-2 cells in vitro with maximal (approximately 30%) increases occurring with dosages of 10(-9) M. In vivo, NT had a transient effect on xenografted MIA PaCa-2 tumour area with increases noted on days 21 and 25 of the study. Conversely, NT significantly stimulated the growth of jejunum and ileum, with a more pronounced effect noted in the jejunum. NT and NMN have similar growth-stimulatory effects on MIA PaCa-2 cells in vitro, which suggests an interaction through the same receptor.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7508319     DOI: 10.1016/s0960-7404(06)80001-0

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  3 in total

1.  Neurotensin receptor 1 signaling promotes pancreatic cancer progression.

Authors:  Kei Takahashi; Shogo Ehata; Kensuke Miyauchi; Yasuyuki Morishita; Keiji Miyazawa; Kohei Miyazono
Journal:  Mol Oncol       Date:  2020-11-20       Impact factor: 6.603

2.  Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy.

Authors:  Zherui Wu; Daniel Martinez-Fong; Jean Trédaniel; Patricia Forgez
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-17       Impact factor: 5.555

3.  Glucagon-like peptide 2 is a potent growth factor for small intestine and colon.

Authors:  D A Litvak; M R Hellmich; B M Evers; N A Banker; C M Townsend
Journal:  J Gastrointest Surg       Date:  1998 Mar-Apr       Impact factor: 3.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.